 HOUSTON--BUSINESS WIRE--Kiromic BioPharma, Inc. Nasdaq: KRBP, an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform Diamond AI to develop novel oncology therapeutics, has announced the completion of the chPD1 licensing agreement with Longwood University. PD-1 has always been a challenge for CAR-T development. PD-1 is the brakes of the immune system, inhibiting immune cells from killing tumor cells. Traditional PD-1 